HOME >> BIOLOGY >> NEWS
UCSF studies illuminate possible new landscape for targeting cancer

Dual UCSF findings dramatize what scientists have just begun to recognize: While so-called oncogenic cells drive the development of cancerous tumors, other, seemingly innocent cells -- inflammatory cells - within emerging tumors can influence the fate of tumors, their aggression and their response to therapy.

The findings, both reported in recent publications, suggest that blocking the action of these 'innocent' cells - or the factors they release - may interrupt the progression of cancerous tumors at early stages of development, the researchers say.

"Tumor biology has historically focused on the cells that contain oncogenic or tumor-suppressor gene mutations. But the combined implication of our two studies suggests that we need to look beyond the mutated tumor cells and into their micro-environment, to take into account the regulation of inflammatory cells," says the lead author of one study, published in Cell, Lisa Coussens, PhD, assistant professor of pathology and a member of the UCSF Comprehensive Cancer Center.

In the Cell study, the researchers report that an enzyme known as matrix metalloproteinase-9 (MMP-9) significantly influences the progression of cancer development in mice engineered to express oncogenes, or tumor-causing genes, that predispose animals to develop squamous cell carcinomas, a common skin cancer in humans. Moreover, the researchers demonstrate that the primary source of the enzyme is not the oncogenic epithelial cells that drive the cancer, but immune inflammatory cells within the tumor's developing mass.

In the other study, published in Nature Cell Biology, the researchers demonstrate that the same enzyme is a key component of the "switch" that initiates angiogenesis, the growth of blood vessels, in mice genetically engineered to develop carcinomas of the pancreatic islets. Angiogenesis supplies emerging tumors with the nutrients and oxygen that are essential for fueling their progressi
'"/>

Contact: Jennifer O'Brien
jobrien@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
14-Mar-2001


Page: 1 2 3 4 5

Related biology news :

1. Rensselaer marks the opening of the center for biotechnology and interdisciplinary studies
2. UCSD undergraduates participate in collaborative studies abroad on cyberinfrastructure
3. Scientist honored for studies of genetic influence on chemotherapy, tumor development
4. $5 million grant funds partnership, studies of minority-based issues in reproductive health
5. Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies
6. $5.5 million awarded to tree-ring research and climate studies
7. Pancreatic cancer blood test & gene studies show promise
8. Two studies weigh in on low-carb diets
9. Animal studies show promise treating severe chronic pain
10. New studies show Curves Program raises metabolic rate in overweight and sedentary women
11. Florida Tech researchers win $912,700 grant for cell studies

Post Your Comments:
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/24/2015)... CAPE TOWN, South Africa , August 24, 2015 /PRNewswire/ ... awarded Germany ,s largest biometrics manufacturer DERMALOG ... with the "2015 African Biometrics Company of the ... installation in Nigeria .   ... ) and http://www.presseportal.de/nr/8896 - On Thursday ...
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual ... Solutions as number 1,361 in growth for the three years through 2014. Being named ... fastest-growing privately held organizations in the country. , “We are thrilled to make ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... recently presented new data on the relationship of genetics and hypertension at the ... on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
(Date:8/26/2015)... 26, 2015  Platform therapeutic company Symic Biomedical, ... a $1.5M Phase II SBIR grant from the ... its therapeutic agent to reduce arteriovenous fistula (AVF) ... stage renal disease (ESRD) patients undergoing hemodialysis. The ... Diabetes and Digestive and Kidney Diseases (NIDDK), will ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
Cached News: